Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine A Schnabel

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Expert Opinion on Medical Diagnostics|March 14, 2013
Gene expression-based diagnostics for molecular cancer classification of difficult to diagnose tumorsCatherine A Schnabel, Mark G Erlander
Vascular Health and Risk Management|February 27, 2007
Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetesCatherine A Schnabel, Matthew Wintle, Orville Kolterman
Genesis (New York, N.Y. : 2000)|November 5, 2003
Pbx1 is essential for adrenal development and urogenital differentiationCatherine A Schnabel, Licia Selleri, Michael L Cleary
Developmental Biology|February 20, 2003
Pbx1 regulates nephrogenesis and ureteric branching in the developing kidneyCatherine A Schnabel, Robert E Godin, Michael L Cleary
Peptides|March 7, 2006
Immunogenicity of xenopeptide hormone therapiesCatherine A Schnabel, S Edwin Fineberg, Dennis D Kim
Clinical Colorectal Cancer|October 18, 2011
A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profileJohn D Hainsworth, Catherine A Schnabel, Mark G Erlander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast CancerIvana Sestak, Yi Zhang, Brock E Schroeder, et al.
NPJ Breast Cancer|August 11, 2017
Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancerBrock Schroeder, Yi Zhang, Olle Stål, et al.
The Journal of Molecular Diagnostics : JMD|June 29, 2011
Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classificationMark G Erlander, Xiao-Jun Ma, Nicole C Kesty, et al.
The Oncologist|September 7, 2020
Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92-Gene AssayKanwal Raghav, Michael Overman, Graham M Poage, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Expert Opinion on Medical Diagnostics|March 14, 2013
Gene expression-based diagnostics for molecular cancer classification of difficult to diagnose tumorsCatherine A Schnabel, Mark G Erlander
Vascular Health and Risk Management|February 27, 2007
Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetesCatherine A Schnabel, Matthew Wintle, Orville Kolterman
Genesis (New York, N.Y. : 2000)|November 5, 2003
Pbx1 is essential for adrenal development and urogenital differentiationCatherine A Schnabel, Licia Selleri, Michael L Cleary
Developmental Biology|February 20, 2003
Pbx1 regulates nephrogenesis and ureteric branching in the developing kidneyCatherine A Schnabel, Robert E Godin, Michael L Cleary
Peptides|March 7, 2006
Immunogenicity of xenopeptide hormone therapiesCatherine A Schnabel, S Edwin Fineberg, Dennis D Kim
Clinical Colorectal Cancer|October 18, 2011
A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profileJohn D Hainsworth, Catherine A Schnabel, Mark G Erlander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast CancerIvana Sestak, Yi Zhang, Brock E Schroeder, et al.
NPJ Breast Cancer|August 11, 2017
Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancerBrock Schroeder, Yi Zhang, Olle Stål, et al.
The Journal of Molecular Diagnostics : JMD|June 29, 2011
Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classificationMark G Erlander, Xiao-Jun Ma, Nicole C Kesty, et al.
The Oncologist|September 7, 2020
Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92-Gene AssayKanwal Raghav, Michael Overman, Graham M Poage, et al.
Pageof 5